Back to results
US 2006/0078558 A1Published application
Diagnosis, prognosis and treatment of pulmonary diseases
OwnerJeffrey Whitsettinventor
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
OwnerJeffrey Whitsettinventor
Estimating the term…
The present invention provides methods to protect a subject from a respiratory disorder involving an airway obstructive disease such as asthma or chronic obstructive pulmonary disease. Provided are methods to protect a subject from an airway obstructive disease using gene therapy. Methods are provided for supplying FoxA2 function to cells of the lung and airway, such as smooth muscle and epithelial cells, by FoxA2 gene therapy. The FoxA2 gene, a modified FoxA2 gene, or a part of the gene may be introduced into the cell in a vector such that the gene remains extrachromosomal or may be integrated into the subjects chromosomal DNA for expression. These methods provide for administering to a subject in need of such treatment a therapeutically effective amount of a FoxA2 gene, or pharmaceutically acceptable composition thereof, for overexpressing the FoxA2 gene. Such methods of expressing the administered FoxA2 gene in the lungs and airway provide for: (1) preventing or alleving bronchial hyperresponsiveness; (2) preventing or alleving of an airway obstructive disease, e.g., bronchial hyperreactivity, airway hyperresponsiveness, asthma or chronic obstructive pulmonary disorder (“COPD”); (3) reducing the airway resistance response to inhaled natural or synthetic bronchoconstrictors or allergens or to exercise; and (4) enhancing responsiveness (relaxation) of airway tissues to β-agonists.
A method of treating pulmonary disease in a subject comprising the administration to a subject in need of such treatment a therapeutically effective amount of a formulation comprising a FoxA2 therapeutic.
A method for prescribing treatment for airway hyperresponsiveness and/or airflow limitation associated with a respiratory disease involving an inflammatory response in a mammal, comprising:
A method of prophylactically treating a subject at risk of developing an airway hyperresponsiveness and/or airflow limitation associated with a respiratory disease involving an inflammatory response, the method comprising administering to the subject a therapeutically effective amount of a formulation comprising a FoxA2 therapeutic demonstrated to inhibit onset of the respiratory disease.
A method of improving gas exchange in the lungs of a subject comprising identifying a subject for whom an improvement in gas exchange within the lungs would be beneficial;
A formulation for protecting a mammal from airway hyperresponsiveness, airflow limitation and/or airway fibrosis associated with a respiratory disease involving inflammation, comprising an anti-inflammatory agent effective for reducing eosinophilic inflammation and a FoxA2 therapeutic agent selected from the group consisting of:
Dependencies are inferred from the claim text.